Life Molecular Imaging – Website

Innovative PET imaging agents for earlier and improved diagnosis and better characterization of diseases

Search Icon

Search for:

Menu Toggle Icon

Skip to content

Home
About us
Molecular Imaging
- How It Works
- Value of Molecular Imaging
Research & Development
Products
News
- Current News
- Careers

Author: lifemolecular

Life Molecular Imaging Receives Orphan Drug Designations for its Tau Tracer PI-2620 as Diagnostic Tool for Progressive Supranuclear Palsy and Corticobasal Degeneration

20. May 202120. May 2021lifemolecular

Click here to read more: Press release

Life Molecular Imaging announces an ongoing collaboration with UCB for
PI-2620, a novel tau imaging agent, for improved diagnosis of Progressive Supranuclear Palsy

3. March 20213. March 2021lifemolecular

Click here to read more: Press release

Life Molecular Imaging is Proud to Support the New IDEAS Study to Further Demonstrate the Value of Amyloid PET for Diagnosing Alzheimer’s Disease in Diverse Communities

11. December 202011. December 2020lifemolecular

Click here to read more: Press release

Tau-PET Tracer PI-2620 Could Set New Standards for an Improved Diagnosis of Progressive Supranuclear Palsy

7. July 20207. July 2020lifemolecular

Click here to read more: Press release

Life Molecular Imaging announces presentation of new scientific data at the Human Amyloid Imaging Meeting

15. January 202015. January 2020lifemolecular

Click to read more: Research Presented Provides Further Insights into Amyloid and Tau Imaging Agents

Life Molecular Imaging and ITELPHARMA Announce a Strategic Partnership for Supply and Production of NeuraCeq in Puglia, Italy

11. November 2019lifemolecular

Click to read more: Life Molecular Imaging teams up with ITELPHARMA for supply and production of NeuraCeq in Puglia, Italy

Life Molecular Imaging and Positron Pharma Announce a Strategic Partnership for Manufacturing and Distribution of PI-2620 in Chile

14. October 201914. October 2019lifemolecular

Click to read more: Investigational tau imaging agent PI-2620 added to the existing imaging biomarker platform for research studies in Chile. First patients have been examined.

Life Molecular Imaging announces presentation of new research results at the European Association of Nuclear Medicine 2019 Annual Meeting

13. October 201913. October 2019lifemolecular

Click to read more: Research presented provides insights into LMI compounds comprising Neuraceq (florbetaben 18F), PI-2620, RM2, GP1 and FSPG.

Life Molecular Imaging started recruitment for longitudinal Phase 2 Study with the Tau tracer PI-2620

17. September 201913. October 2019lifemolecular

Click to read more: The new study will thoroughly assess the accumulation and spread of Tau depositions in patients with Alzheimer’s disease and in subjects with mild cognitive impairment as visualized by PI-2620 brain uptake

DuChemBio Co. Ltd. and Life Molecular Imaging SA sign a Manufacturing and Supply Agreement for Alzheimer’s Disease Diagnostic Radiopharmaceutical for The Philippines

11. July 201911. July 2019lifemolecular

Read more: NeuraCeq (florbetaben) will be soon available in The Philippines

Posts navigation

← Older posts

© Copyright 2018 Life Molecular Imaging

Data Protection & Cookies. Our site uses cookies.
Click here to learn more: Data protection

Imprint / Data protection

Life Molecular Imaging – Website

Proudly powered by WordPress Theme: Radiate.

Loading Comments...

Write a Comment...

Email (Required)

Name (Required)

Website